PMID- 31504536
OWN - NLM
STAT- MEDLINE
DCOM- 20210708
LR  - 20210708
IS  - 1536-4844 (Electronic)
IS  - 1078-0998 (Linking)
VI  - 26
IP  - 5
DP  - 2020 Apr 11
TI  - Matrix Metalloproteinase 3 Predicts Therapeutic Response in Inflammatory Bowel 
      Disease Patients Treated With Infliximab.
PG  - 756-763
LID - 10.1093/ibd/izz195 [doi]
AB  - BACKGROUND AND AIMS: Inflammatory bowel diseases (IBDs) are treated with anti-TNF 
      agents. Strategies to monitor response to therapy may improve clinical control of 
      the disease and reduce economical costs. Previous evidence suggests cleavage of 
      infliximab (IFX) by Matrix Metalloproteinase 3 (MMP3) as a mechanism leading to 
      loss of response. Our study aimed to evaluate if MMP3 serum levels could be 
      considered an early marker of anti-TNF nonresponse and to analyze the correlation 
      with other biochemical markers of treatment failure such as IFX trough levels and 
      anti-IFX antibodies, inflammatory markers, and albumin levels. METHODS: 
      Retrospectively, 73 IBD patients who had received IFX for at least 1 year were 
      enrolled: 35 patients were responders and 38 were nonresponders at 52 weeks. 
      Clinical and biochemical data (Harvey-Bradshaw index [HBI], Mayo score, body mass 
      index [BMI], C-reactive protein [CRP], fecal calprotectin and albumin levels), 
      MMP3 serum levels, and drug monitoring were assessed at baseline, postinduction, 
      and 52 weeks. RESULTS: The MMP3 levels were similar at baseline (19.83 vs 17.92 
      ng/mL), but at postinduction, patients who failed to respond at 1 year had 
      significantly higher levels than patients who responded (26.09 vs 8.68 ng/mL, P < 
      0.001); the difference was confirmed at week 52 (29.56 vs 11.48 ng/mL, P < 
      0.001). The MMP3 levels tended to be higher in patients without antidrug 
      antibodies than in patients with antidrug antibodies at postinduction and 52 
      weeks. CONCLUSIONS: The MMP3 serum determination may represent an early marker of 
      response to infliximab.
CI  - (c) 2019 Crohn's & Colitis Foundation. Published by Oxford University Press. All 
      rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
FAU - Barberio, Brigida
AU  - Barberio B
AD  - Division of Gastroenterology, Department of Surgery, Oncological and 
      Gastroenterological Sciences, University of Padua, Italy.
FAU - D'Inca, Renata
AU  - D'Inca R
AD  - Division of Gastroenterology, Department of Surgery, Oncological and 
      Gastroenterological Sciences, University of Padua, Italy.
FAU - Facchin, Sonia
AU  - Facchin S
AD  - Division of Gastroenterology, Department of Surgery, Oncological and 
      Gastroenterological Sciences, University of Padua, Italy.
FAU - Dalla Gasperina, Marianna
AU  - Dalla Gasperina M
AD  - Division of Gastroenterology, Department of Surgery, Oncological and 
      Gastroenterological Sciences, University of Padua, Italy.
FAU - Fohom Tagne, Cedric Arsene
AU  - Fohom Tagne CA
AD  - Division of Gastroenterology, Department of Surgery, Oncological and 
      Gastroenterological Sciences, University of Padua, Italy.
FAU - Cardin, Romilda
AU  - Cardin R
AD  - Division of Gastroenterology, Department of Surgery, Oncological and 
      Gastroenterological Sciences, University of Padua, Italy.
FAU - Ghisa, Matteo
AU  - Ghisa M
AD  - Division of Gastroenterology, Department of Surgery, Oncological and 
      Gastroenterological Sciences, University of Padua, Italy.
FAU - Lorenzon, Greta
AU  - Lorenzon G
AD  - Division of Gastroenterology, Department of Surgery, Oncological and 
      Gastroenterological Sciences, University of Padua, Italy.
FAU - Marinelli, Carla
AU  - Marinelli C
AD  - Division of Gastroenterology, Department of Surgery, Oncological and 
      Gastroenterological Sciences, University of Padua, Italy.
FAU - Savarino, Edoardo Vincenzo
AU  - Savarino EV
AD  - Division of Gastroenterology, Department of Surgery, Oncological and 
      Gastroenterological Sciences, University of Padua, Italy.
FAU - Zingone, Fabiana
AU  - Zingone F
AD  - Division of Gastroenterology, Department of Surgery, Oncological and 
      Gastroenterological Sciences, University of Padua, Italy.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - England
TA  - Inflamm Bowel Dis
JT  - Inflammatory bowel diseases
JID - 9508162
RN  - 0 (Albumins)
RN  - 0 (Biomarkers)
RN  - 0 (Gastrointestinal Agents)
RN  - 0 (Leukocyte L1 Antigen Complex)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - B72HH48FLU (Infliximab)
RN  - EC 3.4.24.17 (MMP3 protein, human)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Albumins/analysis
MH  - Biomarkers/blood
MH  - C-Reactive Protein/analysis
MH  - Colitis, Ulcerative/blood/*drug therapy
MH  - Crohn Disease/blood/*drug therapy
MH  - Drug Monitoring/methods
MH  - Feces/chemistry
MH  - Female
MH  - Gastrointestinal Agents/*therapeutic use
MH  - Humans
MH  - Induction Chemotherapy
MH  - Infliximab/*therapeutic use
MH  - Leukocyte L1 Antigen Complex/analysis
MH  - Male
MH  - Matrix Metalloproteinase 3/*blood
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Retrospective Studies
MH  - Treatment Failure
MH  - Young Adult
OTO - NOTNLM
OT  - Metalloproteinase 3
OT  - TNF failure
OT  - inflammatory bowel disease
OT  - infliximab
EDAT- 2019/09/11 06:00
MHDA- 2021/07/09 06:00
CRDT- 2019/09/11 06:00
PHST- 2019/04/28 00:00 [received]
PHST- 2019/09/11 06:00 [pubmed]
PHST- 2021/07/09 06:00 [medline]
PHST- 2019/09/11 06:00 [entrez]
AID - 5556462 [pii]
AID - 10.1093/ibd/izz195 [doi]
PST - ppublish
SO  - Inflamm Bowel Dis. 2020 Apr 11;26(5):756-763. doi: 10.1093/ibd/izz195.